Medtronic gets FDA approval for expanded indication for OmniaSecure

Medtronic (MDT) received U.S. FDA approval for an expanded indication for the OmniaSecure defibrillation lead. Now approved for placement in the left bundle branch area, the lead can be used for conduction system pacing, which closely mimics the heart’s natural physiology. Additionally, patients in need of cardiac resynchronization may benefit from left bundle branch optimized cardiac resynchronization therapy, a novel therapy that combines CSP with left-ventricular pacing to further improve patient outcomes.